ARO-MAPT Subcutaneous Injection Cuts CSF Tau by Up to 73% on Average in Healthy Volunteers

In healthy volunteers, subcutaneous ARO-MAPT produced a mean maximum reduction of 73% in cerebrospinal fluid total Tau protein at day 105, with a maximum reduction of 85%. The source states this is the first clinical validation of an siRNA delivery platform crossing the blood-brain barrier to achieve deep target knockdown in cerebrospinal fluid, intended for Alzheimer's disease and other tauopathies.